Boston Scientific's FARADISE registry study is due to run for another two years before its completion in 2027. Image credit: Mehaniq via Shutterstock.com. · Medical Device Network · Mehaniq via ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
MARLBOROUGH, Mass., Dec. 28, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the FARAPULSE™ ...
With only days left in 2023, Boston Scientific has announced the initiation of the Avant Guard clinical trial to evaluate the safety and effectiveness of its Farapulse Pulsed Field Ablation (PFA) ...
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field ...
Editor's note: This is the first of a two-part series on the Boston Scientific Investor Day presentation. This first part focuses on the company's Farapulse pulsed field ablation system. Part two will ...
Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety and effectiveness of the Farapulse Pulsed Field Ablation (PFA) System as a first-line treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results